A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 [lapatinib] in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 [lapatinib] in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2016 Results of pooled analysis (n=1902) from this and two other trials (see profile 1432 and 1409) published in the Journal of Clinical Oncology
    • 03 Jun 2014 Results (meta-analysis) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top